Medivation/Astellas Confident Xtandi Data Will PREVAIL With Urologists
The companies expect the demonstrated improvement in progression-free survival will be particularly compelling for urologists treating castrate-resistant prostate cancer in patients who have not started chemotherapy.
You may also be interested in...
Medivation/Astellas Will Be Ready For Xtandi To Enter Pre-Chemo Prostate Cancer Setting
The oncology drug has been submitted for approval in the larger chemotherapy-naïve patient population and Medivation intends to increase its sales force to support the launch.
PREVAIL Impresses, But Prostate Docs Wary Of Declaring Victory For Xtandi Over Zytiga
Bullish analysts predicted Xtandi easily wins over first-to-market Zytiga in pre-chemo prostate cancer, based on PREVAIL findings. But in the formal presentation at the ASCO GU meeting, clinicians were more reluctant to compare the two drugs and took a more nuanced interpretation of the data, given the important differences in study designs.
Japan Earnings Highlights: New Products Win The Day For Top Pharma
PharmAsia News brings highlights from Japan’s week of earnings presentations.